Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 132Neoplasms 114Prostatic Neoplasms 63Lung Neoplasms 47Head and Neck Neoplasms 46Colorectal Neoplasms 35Ovarian Neoplasms 33Uterine Cervical Neoplasms 28Endometrial Neoplasms 23Motor Activity 22Neoplasm Metastasis 20Multiple Myeloma 19Brain Neoplasms 19Pancreatic Neoplasms 18Rectal Neoplasms 17Lymphoma 16Fatigue 16Carcinoma, Non-Small-Cell Lung 16Pain 15Gastrointestinal Neoplasms 15Colonic Neoplasms 15Leukemia 14Depression 14Oropharyngeal Neoplasms 13Urinary Bladder Neoplasms 12Melanoma 12Hematologic Neoplasms 12Esophageal Neoplasms 12Anxiety Disorders 12Stomach Neoplasms 11

Interventions

toripalimab 1durvalumab 1advexin 1Surveys and Questionnaires 1Sampling Studies 1Nivolumab 1Mitomycin 1Mastectomy, Subcutaneous 1Magnetic Resonance Imaging 1Gemcitabine 1Erlotinib Hydrochloride 1Docetaxel 1Cystoscopy 1Cholecalciferol 1Blood Specimen Collection 1Biopsy 1Aminolevulinic Acid 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma in Situ × Surveys and Questionnaires × Clear all
NCT03106610 2018-05-24

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

M.D. Anderson Cancer Center

Phase 1 Terminated
1 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡